Artiva Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies. The company's lead candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in clinical trials for conditions such as rheumatoid arthritis, systemic lupus erythematosus, and B-cell non-Hodgkin lymphoma. Artiva's pipeline also includes CAR-NK cell candidates, such as AB-201 and AB-205, which target solid tumors and hematological malignancies. Founded in 2019 as a spin-out from South Korea's GC Cell, Artiva leverages a strategic partnership for exclusive rights to GC Cell's NK cell manufacturing technology across most global markets. The company operates primarily out of its headquarters in San Diego, California.
